论文部分内容阅读
目的探讨促甲状腺激素抑制疗法对甲状腺癌患者s IL-2R、CD44V6、TSGF、外周血T淋巴细胞亚群及预后的影响。方法分析本院2014年1月-2016年1月收治的60例甲状腺癌患者临床资料,依据治疗措施不同进行分组,对照组(甲状腺素替代治疗)30例和观察组(促甲状腺激素抑制疗法)30例。结果 2组甲状腺癌患者治疗前s IL-2R、CD44V6、TSGF、CD3~+、CD4~+、CD8~+差异均无统计学意义(P>0.05);治疗后对照组和观察组甲状腺癌患者s IL-2R、CD44V6、TSGF、CD8~+均低于治疗前,CD3~+、CD4~+均高于治疗前,观察组甲状腺癌患者治疗后s IL-2R、CD44V6、TSGF均低于对照组,观察组甲状腺癌患者治疗后CD3~+、CD4~+均高于对照组,CD8~+低于对照组,观察组甲状腺癌患者1年后复发率、转移率均低于对照组(P<0.05),上述差异均有统计学意义。结论促甲状腺激素抑制疗法在甲状腺癌患者中应用,可以明显的改善患者的s IL-2R、CD44V6、TSGF、外周血T淋巴细胞亚群,提高患者预后水平,值得临床推广应用。
Objective To investigate the effects of thyrotropin-inhibiting therapy on the levels of IL-2R, CD44V6, TSGF, T lymphocyte subsets and prognosis in thyroid cancer patients. Methods The clinical data of 60 patients with thyroid carcinoma treated in our hospital from January 2014 to January 2016 were analyzed retrospectively. Thirty patients in the control group (thyroxine replacement therapy) and 30 patients in the observation group (thyroid hormone suppression therapy) 30 cases. Results There was no significant difference in sIL-2R, CD44V6, TSGF, CD3 +, CD4 +, CD8 + before treatment in the two groups of thyroid cancer patients (P> 0.05). After treatment, the thyroid cancer patients The levels of IL-2R, CD44V6, TSGF and CD8 ~ + were lower in the thyroid cancer patients than those in the control group before treatment The levels of CD3 ~ + and CD4 ~ + in thyroid cancer patients after treatment were significantly higher than those in control group and CD8 ~ + in control group. The recurrence rate and metastasis rate in thyroid cancer patients after one year were lower than those in control group (P <0.05), the above differences were statistically significant. Conclusion Thyroid-stimulating hormone suppressive therapy can be used to treat patients with thyroid cancer. It can significantly improve the level of sIL-2R, CD44V6, TSGF and T lymphocyte subsets in patients with thyroid cancer and improve the prognosis of patients with thyroid cancer. It is worthy of clinical application.